Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.137
Sell
RSI(14)
45.993
Neutral
STOCH(KDJ)(9,3,3)
49.008
Neutral
ATR(14)
1.431
High Vlolatility
CCI(14)
17.390
Neutral
Williams %R
74.449
Sell
TRIX(12,20)
-0.428
Sell
StochRSI(14)
65.217
Sell
Dbv Technologies SA
DBVT20.000USD
-0.210-1.04%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
547.26MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Dbv Technologies SA
Currency: USD Updated: 2026-03-27Key Insights
Dbv Technologies SA's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 94 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 39.16.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Dbv Technologies SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Dbv Technologies SA Highlights
StrengthsRisks
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.64M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.64M.
Overvalued
The company’s latest PE is -3.80, at a high 3-year percentile range.
Held by Steven Cohen
Star Investor Steven Cohen holds 0.00 shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
36.823
Target Price
+82.20%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Dbv Technologies SA is 7.43, ranking 107 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 645.00K, representing a year-over-year increase of 26.22%, while its net profit experienced a year-over-year increase of 94.78%.
Score
Financials
8.36
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.12
Operational Efficiency
3.14
Growth Potential
10.00
Shareholder Returns
7.54
Dbv Technologies SA's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Dbv Technologies SA is 6.51, ranking 120 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -3.80, which is -41.80% below the recent high of -2.21 and -406.52% above the recent low of -19.24.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 94/157
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Dbv Technologies SA is 7.67, ranking 98 out of 157 in the Pharmaceuticals industry. The average price target is 20.00, with a high of 35.00 and a low of 7.94.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
36.823
Target Price
+82.20%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Dbv Technologies SA
DBVT
6
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
34
Gilead Sciences Inc
GILD
32
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Dbv Technologies SA is 6.94, ranking 50 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 23.16 and the support level at 17.72, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
20.044
Sell
MA10
19.840
Buy
MA20
20.900
Sell
MA50
21.536
Sell
MA100
18.892
Buy
MA200
14.876
Buy
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Dbv Technologies SA is 3.00, ranking 93 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 4.68%, representing a quarter-over-quarter decrease of 26.29%. The largest institutional shareholder is Steven Cohen, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Dbv Technologies SA is 2.46, ranking 125 out of 157 in the Pharmaceuticals industry. The company's beta value is -0.93. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
-0.91
VaR
+6.67%
240-Day Maximum Drawdown
+32.58%
240-Day Volatility
+108.67%
Return
Best Daily Return
60 days
+10.77%
120 days
+25.42%
5 years
+79.56%
Worst Daily Return
60 days
-12.02%
120 days
-12.02%
5 years
-48.52%
Sharpe Ratio
60 days
+0.51
120 days
+1.57
5 years
+0.19
Risk Assessment
Maximum Drawdown
240 days
+32.58%
3 years
+89.48%
5 years
+96.25%
Return-to-Drawdown Ratio
240 days
+5.32
3 years
+0.00
5 years
-0.14
Skewness
240 days
+1.15
3 years
+2.51
5 years
+2.90
Volatility
Realised Volatility
240 days
+108.67%
5 years
+109.77%
Standardised True Range
240 days
+5.58%
5 years
+5.29%
Downside Risk-Adjusted Return
120 days
+326.12%
240 days
+326.12%
Maximum Daily Upside Volatility
60 days
+64.10%
Maximum Daily Downside Volatility
60 days
+67.89%
Liquidity
Average Turnover Rate
60 days
+0.03%
120 days
+0.24%
5 years
--
Turnover Deviation
20 days
-88.84%
60 days
-89.93%
120 days
-23.10%
Peer Comparison
Pharmaceuticals
Dbv Technologies SA
DBVT
6.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Innoviva Inc
INVA
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
